Study #PA15-0575
Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Monoclonal Gammopathy of Undetermined Significance;Smoldering Plasma Cell Myeloma
Study phase:
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.